Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ATNM |
---|---|---|
09:32 ET | 8757 | 8.18 |
09:34 ET | 5400 | 8.12 |
09:36 ET | 735 | 8.155 |
09:38 ET | 100 | 8.1328 |
09:39 ET | 5610 | 8.145 |
09:43 ET | 1000 | 8.1359 |
09:45 ET | 422 | 8.17 |
09:48 ET | 200 | 8.155 |
09:50 ET | 2000 | 8.09 |
09:52 ET | 400 | 8.12 |
09:56 ET | 1086 | 8.11 |
09:57 ET | 800 | 8.11 |
09:59 ET | 853 | 8.118 |
10:03 ET | 523 | 8.142 |
10:06 ET | 1335 | 8.142 |
10:08 ET | 1122 | 8.13 |
10:10 ET | 300 | 8.105 |
10:12 ET | 2283 | 8.0413 |
10:14 ET | 956 | 8.02 |
10:15 ET | 2115 | 8.03 |
10:17 ET | 1900 | 7.98 |
10:19 ET | 33030 | 7.915 |
10:21 ET | 1409 | 7.89 |
10:24 ET | 3139 | 7.86 |
10:26 ET | 4000 | 7.9 |
10:28 ET | 1563 | 7.9088 |
10:30 ET | 1156 | 7.94 |
10:32 ET | 1862 | 7.9559 |
10:33 ET | 900 | 7.92 |
10:35 ET | 11130 | 7.97 |
10:37 ET | 4376 | 7.99 |
10:42 ET | 255 | 7.98 |
10:48 ET | 5542 | 7.98 |
10:50 ET | 100 | 7.98 |
10:53 ET | 955 | 7.9636 |
10:55 ET | 800 | 7.99 |
10:57 ET | 6656 | 7.99 |
11:00 ET | 2125 | 7.99 |
11:04 ET | 2795 | 7.96 |
11:08 ET | 100 | 7.91 |
11:09 ET | 1000 | 7.915 |
11:11 ET | 1000 | 7.92 |
11:13 ET | 4436 | 7.92 |
11:18 ET | 200 | 7.935 |
11:22 ET | 2624 | 7.935 |
11:24 ET | 100 | 7.92 |
11:26 ET | 226 | 7.935 |
11:27 ET | 11838 | 7.88 |
11:29 ET | 900 | 7.88 |
11:31 ET | 454 | 7.89 |
11:33 ET | 2527 | 7.89 |
11:36 ET | 905 | 7.87 |
11:38 ET | 1900 | 7.88 |
11:45 ET | 4834 | 7.92 |
11:51 ET | 1123 | 7.93 |
11:54 ET | 700 | 7.94 |
11:56 ET | 200 | 7.94 |
11:58 ET | 6363 | 7.945 |
12:00 ET | 3288 | 7.97 |
12:02 ET | 110 | 7.98 |
12:03 ET | 4790 | 7.99 |
12:05 ET | 742 | 8 |
12:07 ET | 1440 | 7.98 |
12:09 ET | 16092 | 7.9 |
12:12 ET | 100 | 7.905 |
12:16 ET | 4004 | 7.825 |
12:18 ET | 1605 | 7.801 |
12:20 ET | 300 | 7.83 |
12:32 ET | 300 | 7.83 |
12:36 ET | 4615 | 7.785 |
12:38 ET | 100 | 7.77 |
12:41 ET | 4690 | 7.75 |
12:43 ET | 1368 | 7.75 |
12:52 ET | 1500 | 7.78 |
12:56 ET | 700 | 7.8 |
12:59 ET | 200 | 7.79 |
01:01 ET | 1142 | 7.79 |
01:15 ET | 553 | 7.785 |
01:17 ET | 1371 | 7.78 |
01:24 ET | 5300 | 7.82 |
01:26 ET | 500 | 7.82 |
01:28 ET | 2151 | 7.86 |
01:30 ET | 304 | 7.85 |
01:32 ET | 227 | 7.8588 |
01:37 ET | 200 | 7.84 |
01:44 ET | 100 | 7.83 |
01:46 ET | 3340 | 7.76 |
01:50 ET | 150 | 7.7605 |
01:51 ET | 3611 | 7.74 |
01:53 ET | 6100 | 7.745 |
01:55 ET | 12918 | 7.83 |
01:57 ET | 3000 | 7.835 |
02:00 ET | 600 | 7.85 |
02:04 ET | 100 | 7.88 |
02:06 ET | 200 | 7.88 |
02:15 ET | 600 | 7.8511 |
02:20 ET | 100 | 7.84 |
02:22 ET | 100 | 7.83 |
02:24 ET | 250 | 7.83 |
02:26 ET | 4408 | 7.78 |
02:27 ET | 100 | 7.78 |
02:29 ET | 8381 | 7.82 |
02:38 ET | 337 | 7.81 |
02:40 ET | 200 | 7.82 |
02:45 ET | 4702 | 7.795 |
02:47 ET | 1000 | 7.7998 |
02:49 ET | 100 | 7.795 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Actinium Pharmaceuticals Inc | 217.7M | -4.1x | --- |
Ovid Therapeutics Inc | 215.7M | -4.2x | --- |
Omeros Corp | 215.0M | -1.2x | --- |
Design Therapeutics Inc | 220.9M | -3.3x | --- |
Merrimack Pharmaceuticals Inc | 214.3M | -179.1x | --- |
INmune Bio Inc | 209.6M | -7.7x | --- |
Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. The Company focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. The Company holds patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $217.7M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 27.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.01 |
EPS | $-1.92 |
Book Value | $2.59 |
P/E Ratio | -4.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.